Dipyrone inhibits neuronal cell death and diminishes hypoxic/ischemic brain injury

Neurosurgery

Volumn 69, Issue 4, 2011, Pages 942-956

  Zhang, Yi ^a   Wang, Xin ^a   Baranov, Sergei V ^a,b   Zhu, Shan ^a   Huang, Zhihong ^b   Fellows Mayle, Wendy ^b   Jiang, Jiying ^a   Day, Arthur L ^a,c   Kristal, Bruce S ^a   Friedlander, Robert M ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cerebral ischemia; Cytochrome c release; Dipyrone; Drug screen; Mitochondria; Neuroprotection

Indexed keywords

CASPASE 3; CASPASE 9; CYCLOOXYGENASE 2; CYTOCHROME C; DIPYRONE; INTERLEUKIN 1BETA; NEUROPROTECTIVE AGENT; PROTEIN BCL 2; PROTEIN BID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOTTING, WESTERN; CYCLOOXYGENASE 2; DIPYRONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPOXIA-ISCHEMIA, BRAIN; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS;

EID: 80053645526     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e318222afb2     Document Type: Article

References (46)

1. Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: A prospective registry. Neurology. 1978;28(8):754-762.
2. Scorrano L, Oakes SA, Opferman JT, et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: A control point for apoptosis. Science. 2003;300(5616): 135-139.
3. Silvestrelli G, Corea F, Paciaroni M, et al. The Perugia hospital-based Stroke Registry: Report of the 2nd year. Clin Exp Hypertens. 2002;24(7-8):485-491.
4. Benchoua A, Guegan C, Couriaud C, et al. Specific caspase pathways are activated in the two stages of cerebral infarction. J Neurosci. 2001;21(18):7127-7134.
5. Brenner C, Kroemer G. Apoptosis. Mitochondria-the death signal integrators. Science. 2000;289(5482):1150-1151.
6. Kristal BS, Stavrovskaya IG, Narayanan MV, et al. The mitochondrial permeability transition as a target for neuroprotection. J Bioenerg Biomembr. 2004;36(4):309-312.
7. Stavrovskaya IG, Kristal BS. The powerhouse takes control of the cell: Is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death? Free Radic Biol Med. 2005;38(6):687-697.
8. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science. 1997;275(5303):1132-1136.
9. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell. 1996;86(1): 147-157.
10. Martinou I, Desagher S, Eskes R, et al. The release of cytochrome c from mitochondria during apoptosis of NGF-deprived sympathetic neurons is a reversible event. J Cell Biol. 1999;144(5):883-889.
11. Plesnila N, Zhu C, Culmsee C, Groger M, Moskowitz MA, Blomgren K. Nuclear translocation of apoptosis-inducing factor after focal cerebral ischemia. J Cereb Blood Flow Metab. 2004;24(4):458-466.
12. Jemmerson R, Dubinsky JM, Brustovetsky N. Cytochrome C release from CNS mitochondria and potential for clinical intervention in apoptosis-mediated CNS diseases. Antioxid Redox Signal. 2005;7(9-10):1158-1172.
13. Ferrer I, Planas AM. Signaling of cell death and cell survival following focal cerebral ischemia: Life and death struggle in the penumbra. J Neuropathol Exp Neurol. 2003;62(4):329-339.
14. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med. 2003;348(14):1365-1375.
15. Narayanan MV, Zhang W, Stavrovskaya IG, Kristal BS, Friedlander RM. Promethazine: A novel application as a neuroprotectant that reduces ischemiamediated injury by inhibiting mitochondrial dysfunction. Clin Neurosurg. 2004; 51:102-107.
16. Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A. 2004;101(9):3071-3076.
17. Zhang WH, Wang H, Wang X, et al. Nortriptyline protects mitochondria and reduces cerebral ischemia/hypoxia injury. Stroke. 2008;39(2):455-462.
18. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417(6884):74-78.
19. Wang X, Zhu S, Pei Z, et al. Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J Neurosci. 2008;28(38):9473- 9485.
20. Brogden RN. Pyrazolone derivatives. Drugs. 1986;32(suppl 4):60-70.
21. Brune K. Comparative pharmacology of 'non-opioid' analgesics. Med Toxicol. 1986;1(Suppl 1):1-9.
22. Schug SA, Manopas A. Update on the role of non-opioids for postoperative pain treatment. Best Pract Res Clin Anaesthesiol. 2007;21(1):15-30.
23. Arellano F, Sacristan JA. Metamizole: Reassessment of its therapeutic role. Eur J Clin Pharmacol. 1990;38(6):617-619.
24. De Souza GE, Cardoso RA, Melo MC, et al. A comparative study of the antipyretic effects of indomethacin and dipyrone in rats. Inflamm Res. 2002;51(1):24-32.
25. Pierre SC, Schmidt R, Brenneis C, Michaelis M, Geisslinger G, Scholich K. Inhibition of cyclooxygenases by dipyrone. Br J Pharmacol. 2007;151(4):494-503.
26. Shimada SG, Otterness IG, Stitt JT. A study of the mechanism of action of the mild analgesic dipyrone. Agents Actions. 1994;41(3-4):188-192.
27. Coimbra C, Drake M, Boris-Moller F, Wieloch T. Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/ antipyretic drug. Evidence for chronic encephalopathic processes following ischemia. Stroke. 1996;27(9):1578-1585.
28. Zhang WH, Wang X, Narayanan M, et al. Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death. Proc Natl Acad Sci U S A. 2003;100(26):16012-16017.
29. Friedlander RM, Gagliardini V, Hara H, et al. Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Exp Med. 1997;185(5):933-940.
30. Hara H, Friedlander RM, Gagliardini V, et al. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci U S A. 1997;94(5):2007-2012.
31. Zhang Y, Wang L, Li J, Wang XL. 2-(1-Hydroxypentyl)-benzoate increases cerebral blood flow and reduces infarct volume in rats model of transient focal cerebral ischemia. J Pharmacol Exp Ther. 2006;317(3):973-979.
32. Yang G, Chan PH, Chen J, et al. Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke. 1994;25(1):165-170.
33. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab. 1990;10(2):290-293.
34. Will Y, Hynes J, Ogurtsov VI, Papkovsky DB. Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat Protoc. 2006;1(6): 2563-2572.
35. Wang X, Figueroa BE, Stavrovskaya IG, et al. Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. Stroke. 2009;40(5):1877-1885.
36. Guegan C, Vila M, Teismann P, et al. Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS. Mol Cell Neurosci. 2002;20(4): 553-562.
37. Zhu S, Li M, Figueroa BE, et al. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J Neurosci. 2004;24(26): 5909-5912.
38. Stavrovskaya IG, Narayanan MV, Zhang W, et al. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med. 2004;200(2):211-222.
39. Kuida K, Lippke JA, Ku G, et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science. 1995;267(5206):2000-2003.
40. Li P, Allen H, Banerjee S, et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell. 1995;80(3):401-411.
41. Streit WJ. Microglial response to brain injury: A brief synopsis. Toxicol Pathol. 2000;28(1):28-30.
42. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier constituents: Improvement by minocycline in vivo and in vitro. Stroke. 2006;37(4):1087-1093.
43. Dhib-Jalbut S, Arnold DL, Cleveland DW, et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol. 2006;176(1-2):198-215.
44. Pompeia C, Boaventura MF, Curi R. Antiapoptotic effect of dipyrone on HL-60, Jurkat and Raji cell lines submitted to UV irradiation, arachidonic acid and cycloheximide treatments. Int Immunopharmacol. 2001;1(12):2173-2182.
45. Laporte JR, Carne X. Blood dyscrasias and the relative safety of non-narcotic analgesics. Lancet. 1987;1(8536):809.
46. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA. 1986;256(13):1749-1757.